Group 1 - Harbin Air Conditioning plans to transfer 40% equity of its subsidiary, Harbin Fushanchuan Biotechnology Development Co., Ltd. The subsidiary reported a net profit of -16.0963 million yuan for 2024, which is 218.83% of the previous year's net profit absolute value [1] - Xinhua Insurance expects a net profit of 29.986 billion to 34.122 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 45% to 65% [1][2] - Gansu Energy anticipates a net profit of 1.55 billion to 1.6 billion yuan for the first three quarters of 2025, reflecting a year-on-year increase of 11.86% to 15.47% [2][3] Group 2 - Dongfang Tower forecasts a net profit of 750 million to 900 million yuan for the first three quarters of 2025, indicating a year-on-year growth of 60.83% to 93% [4] - Meili Eco announced that its subsidiary won a bid for an EPC project worth 2.375 billion yuan [6] - Bohai Chemical's wholly-owned subsidiary will undergo routine maintenance for its 600,000 tons/year PDH unit, expected to last about 30 days [8] Group 3 - Qin Port Co. reported a total throughput of 317.02 million tons for the first nine months of 2025, a year-on-year increase of 5.56% [10] - Jianglong Shipbuilding won a bid for a 72.99 million yuan fishery enforcement vessel project, accounting for 4.22% of its 2024 audited revenue [11] - Longyuan Technology expects a net profit of 35 million to 40 million yuan for the first three quarters of 2025, representing a year-on-year increase of 50.11% to 71.55% [12] Group 4 - Naipu Mining anticipates a net profit of 61 million to 66 million yuan for the first three quarters of 2025, reflecting a year-on-year decline of 45.16% to 49.32% [14] - Jinggong Steel Structure reported a cumulative contract amount of 17.98 billion yuan for the first nine months of 2025, a year-on-year increase of 4.8% [15][16] - Shenzhen Gas reported a net profit of 918 million yuan for the first three quarters of 2025, a year-on-year decrease of 13.08% [17] Group 5 - Yabao Pharmaceutical's subsidiary received a drug registration certificate for a new diabetes medication [18] - Shaanxi Coal's coal production in September was 14.56 million tons, a year-on-year increase of 5.34% [20] - Sifang New Materials reported a 15.94% year-on-year decline in concrete production for the first three quarters [22] Group 6 - Nanjing Foods reported a consolidated revenue of 276 million yuan in September, a slight increase of 0.0016% year-on-year [23] - Pulaike received a new veterinary drug registration certificate for a flea and tick treatment [24] - Zhucheng Technology received a cash dividend of 15 million yuan from its subsidiary [25] Group 7 - David Medical's subsidiary received a medical device registration certificate for a portable electronic endoscope image processor [26] - Zhongtong Bus reported a 36.88% year-on-year increase in sales in September, totaling 1,106 units [27] - Xiantan Co. reported a 11.95% year-on-year increase in chicken sales revenue in September [28] Group 8 - Bojun Technology expects a net profit of 552 million to 662 million yuan for the first three quarters of 2025, a year-on-year increase of 50% to 80% [30] - Haishi Pharmaceutical's innovative pain relief drug clinical trial application has been accepted [31] - Lingxiao Pump Industry used 80 million yuan of idle funds to purchase financial products [32] Group 9 - Qiangda Circuit's subsidiary completed business registration changes to expand its operational scope [33] - *ST Tianyu's controlling shareholder applied for bankruptcy liquidation due to severe financial difficulties [34] - Baolidi's shareholder plans to reduce holdings by up to 1 million shares [36] Group 10 - Zijin Mining completed the acquisition of Kazakhstan's Raygorodok gold mine, controlling 100% of its rights [44] - Zhonggang Luoyang's indirect controlling shareholder completed a capital increase, raising registered capital from approximately 26.666 billion yuan to 44.824 billion yuan [46] - Jinyu Jidong's director resigned due to work adjustments [47]

Core Viewpoint - The approval of "Fluralaner Drops" as a new veterinary drug by the Ministry of Agriculture and Rural Affairs marks a significant development for the company and its subsidiary, enhancing their product portfolio in the veterinary medicine sector [1] Group 1: Regulatory Approval - The Ministry of Agriculture and Rural Affairs has approved the joint application for "Fluralaner Drops" by the company and its wholly-owned subsidiary, Luoyang Huizhong Veterinary Medicine Co., Ltd [1] - The new veterinary drug is set to be officially registered with the issuance of the New Veterinary Drug Registration Certificate on October 11, 2025 [1] Group 2: Indications and Usage - "Fluralaner Drops" is indicated for the treatment of flea (Ctenocephalides felis) and tick (Rhipicephalus sanguineus, Ixodes ricinus) infestations [1] - The product can be used as part of the clinical treatment plan for Flea Allergy Dermatitis (FAD) [1]

证券代码：603566 证券简称：普莱柯 公告编号：2025-041 普莱柯生物工程股份有限公司 关于获得新兽药注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《兽药管理条例》和《兽药注册办法》规定，经农业农村部审查，批准 普莱柯生物工程股份有限公司（以下简称"公司"）及其全资子公司洛阳惠中兽 药有限公司（以下简称"惠中兽药"）等单位联合申报的"氟雷拉纳滴剂"为新 兽药，并于 2025 年 10 月 11 日公示了核发《新兽药注册证书》（中华人民共和 国农业农村部公告第 957 号）事项。详情如下： 一、新兽药的基本信息 新兽药名称：氟雷拉纳滴剂 注册分类：二类 体重 BW（kg） 规格 数量（支） 1.2≤BW≤2.8 0.4ml∶氟雷拉纳 0.1125g 1 2.86.25 选择合适的规格组合使用 表 1 猫按体重推荐使用剂量表 跳蚤和蜱虫是寄生于猫体表的常见体外寄生虫，通过口器吸血导致皮肤损伤 与贫血，也是多种病原的重要携带者；如经蜱虫传播的蜱媒疾病有粒细胞无形体 病、莱姆病、巴贝斯虫病等，其中部分为 ...

证券代码：603566 证券简称：普莱柯 公告编号：2025-042 普莱柯生物工程股份有限公司 关于获得新兽药注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《兽药管理条例》和《兽药注册办法》规定，经农业农村部审查，批准 普莱柯生物工程股份有限公司（以下简称"公司"）及其全资子公司洛阳惠中生 物技术有限公司（以下简称"惠中生物"）等单位联合申报的"鸡新城疫、传染 性支气管炎、禽流感（H9 亚型）、禽腺病毒病（I 群，4 型）四联灭活疫苗（N7a 株+M41 株+SZ 株+Fiber-2 蛋白）"为新兽药，并于 2025 年 10 月 11 日公示了核 发《新兽药注册证书》（中华人民共和国农业农村部公告第 957 号）事项。详情 如下： 一、新兽药的基本信息 新兽药名称：鸡新城疫、传染性支气管炎、禽流感（H9 亚型）、禽腺病毒 病（I 群，4 型）四联灭活疫苗（N7a 株+M41 株+SZ 株+Fiber-2 蛋白） 注册分类：三类 主要成分与含量：疫苗中含有灭活的鸡新城疫病毒 N7a 株、传染性支气管 炎 ...

Core Viewpoint - The company, Pulaike (603566), has received approval from the Ministry of Agriculture and Rural Affairs for a new veterinary drug, a four-in-one inactivated vaccine for poultry diseases, marking a significant development in the veterinary pharmaceutical industry [1] Group 1: Company Developments - Pulaike and its wholly-owned subsidiary, Luoyang Huizhong Biotechnology Co., Ltd., jointly applied for the new veterinary drug, which includes vaccines for Newcastle disease, infectious bronchitis, avian influenza (H9 subtype), and avian adenovirus disease [1] - The new veterinary drug registration certificate was publicly announced on October 11, indicating successful regulatory approval [1] Group 2: Market Context - As of now, there are no similar four-in-one inactivated vaccine products available for sale in the poultry market, highlighting a potential competitive advantage for the company [1]

Core Viewpoint - The approval of "Fluralaner Drops" as a new veterinary drug by the Ministry of Agriculture and Rural Affairs marks a significant development for the company and its wholly-owned subsidiary, Luoyang Huizhong Veterinary Medicine Co., Ltd, as it addresses a gap in the market for flea and tick treatment in cats [1] Company Summary - The company, 普莱柯 (603566), has received official approval for its new veterinary drug, "Fluralaner Drops," which is intended for the treatment of flea and tick infections in cats [1] - The drug has been registered and the registration certificate was publicly announced on October 11 [1] Industry Summary - As of now, there are no similar products available in the market, indicating a potential competitive advantage for the company in the veterinary pharmaceutical sector [1]

Core Viewpoint - The Ministry of Agriculture and Rural Affairs has approved the new veterinary drug registration for a four-in-one inactivated vaccine developed by Pulaike Bioengineering Co., Ltd. and its subsidiary Huizhong Bio, which targets multiple poultry diseases [1] Group 1: Product Development - The four-in-one inactivated vaccine addresses Newcastle disease, infectious bronchitis, avian influenza (H9 subtype), and avian adenovirus disease (Group I, Type 4) [1] - The total investment in the product development amounts to 7.3635 million yuan [1] - The vaccine provides immunity for at least six months with a single injection [1] Group 2: Market Position - Currently, there are no similar four-in-one inactivated vaccines for poultry available in the market [1] - The acquisition of the new veterinary drug registration certificate is expected to enhance the company's product competitiveness [1] - This development is anticipated to create a new growth point for the company's performance [1]

Core Points - The company announced a cash dividend distribution of 0.2 yuan per share (including tax) for the first half of 2025, approved at the first extraordinary general meeting of shareholders on September 16, 2025 [2][3] - The total cash dividend to be distributed amounts to approximately 68.38 million yuan (including tax), based on the number of shares eligible for distribution, which is 341,919,373 shares [3][4] - The company will not issue bonus shares or increase capital reserves during this distribution [3][4] Distribution Plan - The distribution is for the fiscal year of the first half of 2025, targeting all shareholders registered with the China Securities Depository and Clearing Corporation Limited Shanghai Branch as of the close of trading on the day before the equity registration date [2][3] - The reference price for the ex-dividend (ex-rights) will be calculated based on the formula: (previous closing price - cash dividend) / (1 + change in circulating shares ratio), with the cash dividend per share calculated as approximately 0.1976 yuan [3][6] Taxation Details - For individual shareholders holding unrestricted circulating shares, dividends are subject to different tax treatments based on the holding period, with those holding for over one year exempt from personal income tax [7][8] - For qualified foreign institutional investors (QFII), a 10% withholding tax will apply, resulting in a net cash dividend of 0.18 yuan per share after tax [9][10] - Other institutional investors and corporate shareholders will not have taxes withheld by the company, and the actual cash dividend remains at 0.20 yuan per share [10]

北京德恒律师事务所 关于普莱柯生物工程股份有限公司 北京德恒律师事务所 关于普莱柯生物工程股份有限公司差异化分红事项的法律意见 北京德恒律师事务所 关于普莱柯生物工程股份有限公司 差异化分红事项的 法律意见 北京市西城区金融街 19 号富凯大厦 B 座 12 层 电话：010-52682888 传真：010-52682999 邮编：100033 差异化分红事项的 法律意见 德恒 01G20240892-03 号 致：普莱柯生物工程股份有限公司 北京德恒律师事务所（以下简称"本所"）接受普莱柯生物工程股份有限公 司（以下简称"普莱柯"或"公司"）的委托，根据《中华人民共和国公司法》 （以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券 法》"）、《上海证券交易所上市公司自律监管指引第 7 号—回购股份》等有 关法律法规、规范性文件和《普莱柯生物工程股份有限公司章程》（以下简称"《公 司章程》"）的相关规定，按照律师行业公认的业务标准、道德规范和勤勉尽责 精神，就公司 2025 年半年度利润分配所涉及的差异化分红（以下简称"本次差 异化分红"）相关事项出具本法律意见。 为出具本法律意见，本所律师 ...

证券代码：603566 证券简称：普莱柯 公告编号：2025-040 普莱柯生物工程股份有限公司 2025年半年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 每股分配比例 A 股每股现金红利0.2元（含税） 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/10/16 | － | 2025/10/17 | 2025/10/17 | 差异化分红送转： 是 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 9 月 16 日的2025年第一次临时股东大会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 重要内容提示： 3. 差异化分红送转方案： （1）根据《上海证券交易所上市公司自律监管指引第 7 号——回购股份》的有关规定, 上市 ...